

# BioVaxys Announces Form 211 Clearance For OTC Trading in the USA

Vancouver, British Columbia--(Newsfile Corp. - December 10, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that its submission of Form 211 to FINRA has been cleared and the Company's shares now qualify for trading in the United States on the OTC Pink Market under the symbol "LMNGF". The Company has also made an application for its common shares to be DTC eligible and expects to receive this designation within the next 30 days.

James Passin, CEO of BioVaxys, stated, "We are pleased to increase liquidity for shareholders with the OTC quotation and look forward to increasing our Company's visibility in US capital markets.

## About BioVaxys Technology Corp.

Based in Vancouver, [BioVaxys Technology Corp.](#), a British Columbia-registered biotechnology company, is a world leader in haptenized protein vaccines that is developing viral and oncology vaccine platforms as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys common shares trade on the CSE under the stock symbol "BIOV" and are listed on the Frankfurt Bourse (FRA: 5LB).

ON BEHALF OF THE BOARD

Signed "James Passin"

James Passin, CEO  
+1 646 452 7054

## Media Contacts

Andrea Vuturo  
+1 508 301 3774  
[biovoxys@dittopr.co](mailto:biovoxys@dittopr.co)

## Cautionary Statements Regarding Forward Looking Information

*This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the murine model study, regulatory approval for a Phase I study of its BVX-0320 Vaccine Candidate in humans and the overall development of BioVaxys' vaccines, including any haptenized SARS-Cov-2 protein vaccine. **There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those***

**expressed or implied in such forward-looking statements.**

*These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.*

*The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.*

## **BIOVAXYS**

To view the source version of this press release, please visit  
<https://www.newsfilecorp.com/release/69951>